 |
|
Clinical Trial of Tetrahydrozoline HydrochlorideA Valuable New Nasal Decongestant
ISIDORE NEISTADT, M.D.
AMA Arch Otolaryngol. 1955;62(2):143-144.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
This report presents details of a clinical trial of tetrahydrozoline hydrochloride (Tyzine), a new sympathomimetic agent useful in 0.1% aqueous solution as a topical vasoconstrictor and nasal decongestant.
The effectiveness of tetrahydrozoline, as measured by its promptness of action, degree of relief provided, and the percentage of patients benefited, is superior.
The decongestive action of tetrahydrozoline is notably prolonged, so that instillations every four to eight hours, or at longer intervals in some cases, are sufficient to maintain continuous relief; instillation at bedtime provides relief that carries through the night.
Tetrahydrozoline is also free of both local and systemic side-effects.
BACKGROUND
Pharmacologic tests with tetrahydrozoline, which is designated chemically as 2-(1,2,3, 4-tetrahydro-1-naphthyl) imidazoline hydrochloride, suggested that this recently synthesized compound should prove highly effective and free of the disadvantages of its predecessors. The structural formula of tetrahydrozoline is as follows:
Tetrahydrozoline consists structurally of an aromatic nucleus and a side radical
. . . [Full Text PDF of this Article]
Author Affiliations
Valley Stream, N. Y.
Footnotes
Submitted for publication Dec. 6, 1954.
Tetrahydrozoline hydrochloride in 0.1% aqueous solution (Tyzine) for intranasal use was supplied for this study by Dr. F. E. Bishop, of Chas. Pfizer & Company, Inc., Brooklyn, N. Y.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
